Funding for this research was provided by:
vasopharm GmbH (n.a.)
Text and Data Mining valid from 2020-01-14
Received: 18 October 2019
Accepted: 5 December 2019
First Online: 14 January 2020
Ethics approval and consent to participate
: This trial is conducted in patients who are unable to consent, therefore the patient’s legal representative provides consent for the patient according to local regulations (next-of-kin, appointed representative). All patients who have recovered sufficiently will additionally be asked to re-consent.Approval for this protocol has been obtained from the leading ethic committee “Ethikkommission der Medizinischen Universität Innsbruck, Austria” (date of approval 31 May 2016; no. AN2016–0035 359/2.1). Subsequent approval by local and central ethics committees has been obtained according to local regulations (see InternalRef removed).The competent regulatory authorities of all countries have approved the trial.
: As clinical images or other clinical and personal data are not shown, consent for publication is not applicable.
: FT and RS are full-time employees of vasopharm GmbH. The other authors declare that they have no competing interests.